WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2018079966) PHARMACEUTICAL COMPOSITION CONTAINING ICG-001 FOR PREVENTING OR TREATING FIBROSIS
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2018/079966 International Application No.: PCT/KR2017/005739
Publication Date: 03.05.2018 International Filing Date: 01.06.2017
IPC:
A61K 31/519 (2006.01) ,A23L 33/10 (2016.01)
Applicants: INDUSTRY-ACADEMIC COOPERATION FOUNDATION GYEONGSANG NATIONAL UNIVERSITY[KR/KR]; 501, Jinju-daero Jinju-si Gyeongsangnam-do 52828, KR
Inventors: YOON, Tae-Jin; KR
KIM, Kyung-Il; KR
Agent: LEE, Cheo Young; KR
CHANG, Je Hwan; KR
Priority Data:
10-2016-013906525.10.2016KR
Title (EN) PHARMACEUTICAL COMPOSITION CONTAINING ICG-001 FOR PREVENTING OR TREATING FIBROSIS
(FR) COMPOSITION PHARMACEUTIQUE CONTENANT DE L'ICG-001 DESTINÉE À PRÉVENIR OU À TRAITER LA FIBROSE
(KO) ICG-001을 함유하는 섬유증의 예방 또는 치료용 약학 조성물
Abstract: front page image
(EN) The present invention relates to a pharmaceutical composition containing ICG-001 for preventing or treating fibrosis, more specifically to a pharmaceutical composition, containing ICG-001 which powerfully inhibits collagen generation, for preventing or treating dermatofibroma (hypertrophic scarring, keloid, scleroderma, and the like) and systemic fibrotic diseases (pulmonary fibrosis, liver cirrhosis, atrial fibrosis, glial scarring, Crohn's disease, myelofibrosis, systemic fibrosis, and the like). The pharmaceutical composition containing ICG-001 for preventing or treating fibrosis according to the present invention has been confirmed to be a strong inhibitor of collagen synthesis in fibroblasts, and accordingly can be effectively utilized as a therapeutic agent for fibrosis which occur from accumulation of connective tissue, such as collagen and glycosaminoglycans, due to proliferation of fibroblasts.
(FR) La présente invention concerne une composition pharmaceutique contenant de l'ICG-001 afin de prévenir ou de traiter la fibrose, plus particulièrement une composition pharmaceutique, contenant de l'ICG-001 qui inhibe fortement la production de collagène, afin de prévenir ou de traiter le dermatofibrome (la cicatrice hypertrophique, la chéloïde, le scléroderme, et similaires) et les troubles fibrotiques systémiques (la fibrose pulmonaire, la cirrhose hépatique, la fibrose atriale, la cicatrisation gliale, la maladie de Crohn, la myélofibrose, la fibrose systémique, et similaires). Il a été confirmé que la composition pharmaceutique contenant de l'ICG-001 destinée à prévenir ou à traiter la fibrose selon la présente invention est un inhibiteur fort de la synthèse du collagène dans les fibroblastes, et en conséquence peut être efficacement utilisée comme agent thérapeutique pour la fibrose qui se produit à partir de l'accumulation du tissu conjonctif, tel que du collagène et des glycosaminoglycanes, dû à la prolifération des fibroblastes.
(KO) 본 발명은 ICG-001을 함유하는 섬유증의 예방 또는 치료용 약학 조성물에 관한 것으로, 보다 상세하게는 콜라겐의 생성을 강력하게 억제하는 ICG-001을 함유하는 피부 섬유증(비후성 반흔, 켈로이드, 피부 경화증 등) 및 전신 섬유화 질환(폐섬유증, 간경화증, 심방 섬유증, 뇌신경교 반흔, 크론병, 골수 섬유증, 전신 섬유증 등)의 예방 또는 치료용 약학 조성물에 관한 것이다. 본 발명에 따른 ICG-001을 함유하는 섬유증의 예방 또는 치료용 약학 조성물은, 섬유아세포에서 콜라겐의 합성을 강력하게 억제하는 것을 확인하였으며, 따라서 섬유아세포의 증식에 의해서 콜라겐과 글리코사미노글리칸과 같은 결합조직이 축적되어 발병하는 섬유화 또는 섬유증 치료제로 유용하게 사용될 수 있다.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: Korean (KO)
Filing Language: Korean (KO)